Rho guanine nucleotide exchange factor 10 (ARHGEF10)

Rho guanine nucleotide exchange factor 10 (ARHGEF10) is a member of the Rho GEF family of enzymes that activate Rho GTPases, predominantly RhoA, by stimulating GDP-GTP exchange[1][3][8]. It is critical for neural development, especially for proper myelination of peripheral nerves and nerve conduction velocity[1][3]. Mutations and altered expression in humans are linked to slowed nerve conduction velocity, hereditary motor and sensory neuropathy, autism spectrum disorder, and impaired neural morphogenesis[1][2][3]. Additionally, ARHGEF10 has roles in cell cycle regulation—specifically centrosome duplication—and in vesicular trafficking by directing Rab8 localization to exocytotic vesicles[3][6]. In oncology, ARHGEF10 is characterized as a putative tumor suppressor in pancreatic ductal adenocarcinoma, with loss or reduction of expression promoting tumor proliferation, invasion, and metastasis[5]. ARHGEF10-depleted tumor cells display heightened sensitivity to dasatinib, suggesting potential therapeutic avenues[5]. No approved drugs currently target ARHGEF10 directly; interactions described are primarily preclinical. Key references: [1][2][3][5][6][8]

Other names

ARHGEF10GEF10SNCVKIAA0294Gef10Rho guanine nucleotide exchange factor (GEF) 10

Inhibition of downstream signaling (e.g., Src kinase inhibition via dasatinib reduces motility/invasion in ARHGEF10-deficient cells) [5]